NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis → Warren Buffett & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free EVOK Stock Alerts $0.56 +0.02 (+3.70%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.6050-Day Range$0.43▼$0.6252-Week Range$0.40▼$1.96Volume63,002 shsAverage Volume35,165 shsMarket Capitalization$4.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Evoke Pharma alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesJune 6 at 3:56 AM | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.comJune 4, 2024 | americanbankingnews.comEvoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Up 6.0% in MayMay 29, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.comMay 16, 2024 | globenewswire.comEvoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceMay 15, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comEVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | globenewswire.comEvoke Pharma Reports First Quarter 2024 Financial ResultsMay 11, 2024 | msn.comOprah apologises for being 'major contributor' to diet culture after weight loss drugs admissionApril 26, 2024 | finance.yahoo.comEvoke Pharma, Inc. (EVOK)April 17, 2024 | finance.yahoo.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 17, 2024 | globenewswire.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 10, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsightApril 10, 2024 | msn.comEmpowering students: Innovative approaches to climate change educationApril 10, 2024 | finance.yahoo.comStephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy TeamApril 1, 2024 | msn.comHow a Dubai man built a $200,000 art collection in his Business Bay homeMarch 30, 2024 | msn.comThe Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-ColaMarch 30, 2024 | msn.comBrain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlertMarch 22, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 21, 2024 | marketwatch.comEvoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO GonyerMarch 21, 2024 | finance.yahoo.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerMarch 21, 2024 | globenewswire.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 18, 2024 | msn.comBig change is the only constant in eco: India IncMarch 17, 2024 | seekingalpha.comEvoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | finance.yahoo.comEvoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?March 15, 2024 | msn.comBrain gain: Hope rises with new dementia treatmentsSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-116.75% Pretax Margin-116.75% Return on Equity-4,908.09% Return on Assets-78.43% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.32 Sales & Book Value Annual Sales$5.18 million Price / Sales0.93 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-0.73Miscellaneous Outstanding Shares8,600,000Free Float8,073,000Market Cap$4.82 million OptionableNot Optionable Beta0.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Matthew J. D'Onofrio MBA (Age 54)Co-Founder, CEO & Director Comp: $779.37kDr. Marilyn R. Carlson D.M.D. (Age 76)M.D., RAC., Chief Medical Officer Comp: $681.24kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsApollomicsNASDAQ:APLMMEI PharmaNASDAQ:MEIPKALA BIONASDAQ:KALASynlogicNASDAQ:SYBXAkari TherapeuticsNASDAQ:AKTXView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed in 2024? Evoke Pharma's stock was trading at $1.0503 at the start of the year. Since then, EVOK stock has decreased by 46.7% and is now trading at $0.56. View the best growth stocks for 2024 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 40,700 shares, an increase of 6.0% from the April 30th total of 38,400 shares. Based on an average trading volume of 34,800 shares, the short-interest ratio is presently 1.2 days. Approximately 0.6% of the shares of the company are short sold. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings results on Tuesday, May, 14th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter. The specialty pharmaceutical company had revenue of $1.74 million for the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 4,908.09% and a negative net margin of 116.75%. When did Evoke Pharma's stock split? Shares of Evoke Pharma reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What guidance has Evoke Pharma issued on next quarter's earnings? Evoke Pharma updated its FY 2024 earnings guidance on Tuesday, May, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.1 million. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVOK) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.